Novo Nordisk is a global healthcare company based in Denmark, primarily focused on diabetes care and hormone replacement therapies. Founded in 1923, it has grown to become one of the largest producers of insulin, a critical medication for managing diabetes. The company is dedicated to improving the lives of people with chronic conditions through innovative treatments and research. In addition to diabetes, Novo Nordisk also develops therapies for obesity, hemophilia, and growth disorders. The company emphasizes sustainability and corporate responsibility, aiming to minimize its environmental impact while enhancing access to healthcare worldwide.